| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Institute of Allergy and Infectious Diseases (NIAID) |
| Information provided by: | National Institute of Allergy and Infectious Diseases (NIAID) |
| ClinicalTrials.gov Identifier: | NCT00069485 |
Purpose
The immune systems of some individuals may be capable of resisting HIV infection. These individuals do not appear to be infected with HIV despite multiple sexual encounters with HIV infected partners. This study will examine the immune systems of these individuals to determine what factors are responsible for their ability to resist HIV infection.
Study hypothesis: Some long-term, multiply-exposed seronegative persons have relative resistance to HIV infection maintained by T cell responses.
| Condition |
|
HIV Infections |
| MedlinePlus related topics: | AIDS |
| Study Type: | Observational |
| Study Design: | Natural History, Longitudinal, Defined Population, Prospective Study |
| Official Title: | Evaluation of HIV-Specific Immunological and Virological Responses of HIV-1 Multiply-Exposed Seronegative Individuals |
| Estimated Enrollment: | 100 |
| Study Start Date: | December 1995 |
Rare individuals appear naturally resistant to overt HIV-1 infection despite repeated sexual exposures. These individuals, referred to as exposed seronegatives (ES), represent a unique population in which to evaluate mechanisms by which HIV-1 replication is either controlled or aborted. The purpose of the study is to analyze HIV-specific immune responses, both cellular and humoral, that exist in seronegative individuals who have experienced multiple exposures to HIV by sexual contact.
This study will follow participants for 2 years. Participants will have 25 study visits during the study. Assessments will include HIV tests, viral load measurements, CD4 counts, pregnancy tests, and physical exams.
Eligibility
| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Washington | |||||
| Fred Hutchinson Cancer Research Center / University of Washington HIV Vaccine Trials Unit | Recruiting | ||||
| Seattle, Washington, United States, 98104 | |||||
| Contact: Kim Louis 206-667-2300 klouis@fhcrc.org | |||||
| Principal Investigator: | Julie McElrath, MD, PhD | University of Washington |
More Information
| Study ID Numbers: | 5R01AI47086-03, 5 R01 AI47086-03 |
| First Received: | September 26, 2003 |
| Last Updated: | September 17, 2007 |
| ClinicalTrials.gov Identifier: | NCT00069485 |
| Health Authority: | United States: Federal Government |
|
|
|
|
|
|
